Clopidogrel Tablet, Film Coated
Product Images NDC 71610-527

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 71610-527). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 75 mg (71610 0527 60)

Label for Clopidogrel bisulfate 75 mg film-coated tablets, containing 90 tablets per container. The label indicates storage between 20-25 degrees Celsius and instructs to keep out of reach of children. It is manufactured by Apotex Inc., Toronto, Canada and repackaged by Aphena Pharma Solutions - Tennessee, LLC, Cookeville, TN. Marked as prescription only (RX Only).*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure3.jpg (Figure3)

A hazard ratio forest plot depicting patient baseline characteristics and on-study concomitant medications/interventions for the CURE Study. The horizontal axis shows hazard ratios with confidence intervals for subgroups defined by age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, and previous stroke, comparing Clopidogrel to placebo groups.*

FDA Label Image

Figure3b.jpg (Figure3b)

A hazard ratio forest plot from the CURE study showing patient baseline characteristics and on-study concomitant medications or interventions comparing Clopidogrel and placebo groups. The plot includes subgroups by Heparin/LMWH use, Aspirin dosage, GP IIb/IIIa antagonist use, Beta-blocker use, and ACE inhibitor use, presenting hazard ratios with 95% confidence intervals. The horizontal axis indicates hazard ratios ranging from 0.3 to 1.4, with markers showing HR estimates and confidence intervals for each subgroup.*

FDA Label Image

Figure6.jpg (Figure6)

A forest plot chart titled 'Effects of Adding Clopidogrel to Aspirin on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups for the COMMIT Study'. It shows subgroup analyses by gender, age at entry, hours since onset, systolic blood pressure (SBP), heart rate, and fibrinolytic agent use. The chart presents odds ratios with 99% confidence intervals, comparing Clopidogrel to placebo for each subgroup, displayed as points with horizontal lines on a numeric scale from 0.6 to 1.3.*

FDA Label Image

Figure7.jpg (Figure7)

A line graph titled 'Fatal or Non-Fatal Vascular Events in the CAPRIE Study' showing cumulative event rate percentages on the y-axis and months of follow-up on the x-axis over up to 36 months. The graph compares event rates between two groups labeled Aspirin and Clopidogrel, with the Clopidogrel group showing slightly lower cumulative event rates. A p-value of 0.045 is noted on the graph.*

FDA Label Image

Figure8.jpg (Figure8)

A horizontal forest plot chart titled 'Hazard Ratio and 95% CI by Baseline Subgroups in the CAPRIE Study,' showing hazard ratios with confidence intervals for subgroups Stroke, MI, PAD, and Overall. The x-axis is labeled with hazard ratio values ranging from 0.6 to 1.3 with 1.0 as the reference line. The chart compares Clopidogrel versus Aspirin outcomes for each subgroup.*

FDA Label Image

Clopiodgrel-01.jpg (Clopiodgrel 01)

Chemical structure diagram of clopidogrel bisulfate, showing its molecular arrangement including a thiophene ring, piperidine ring, and chlorine-substituted phenyl group, along with the sulfate component (H2SO4).*

FDA Label Image

Figure-01.jpg (Figure 01)

A forest plot showing the effect of co-administered proton pump inhibitors (PPIs) — dexlansoprazole 60 mg, lansoprazole 30 mg, pantoprazole 80 mg, and omeprazole 80 mg — on the active metabolite exposure (AUC) of clopidogrel 75 mg. The horizontal axis represents change relative to clopidogrel administered alone, with mean effect and 90% confidence intervals displayed for each PPI.*

FDA Label Image

Figure2.jpg (Figure2)

A line graph showing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two curves compare placebo (+ aspirin) and clopidogrel (+ aspirin). The y-axis ranges from 0 to 16%, and the x-axis shows months 0 to 12, with lower event rates for clopidogrel over time. A p-value of 0.00009 is noted.*

FDA Label Image

Figure4.jpg (Figure4)

A cumulative event rate graph showing death rates in the COMMIT Study for Clopidogrel versus placebo. The y-axis represents the percentage dead before first discharge, ranging from 0 to 9%, and the x-axis shows days since randomization (up to 28 days). The graph compares death rates between placebo (8.1%) and Clopidogrel (7.5%), indicating a 7% proportional risk reduction (p=0.03).*

FDA Label Image

Figure5.jpg (Figure5)

A cumulative event rate curve from the COMMIT study showing combined endpoints of re-infarction, stroke, or death over 28 days post-randomization. The graph compares Clopidogrel and placebo groups, with percentage on the y-axis and days on the x-axis. Clopidogrel group shows a lower event rate (9.2%) compared to placebo (10.1%).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.